The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin.

Trial Profile

The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Teicoplanin (Primary)
  • Indications Septicaemia; Staphylococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2010 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 14 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Jul 2009 Sponser (sanofi-aventis) added, additional lead trial centres and investigators identified as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top